Market research
MNOV MediciNova Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 68M
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- Not available
- Beta
- 0.62
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US58468P2065
- Market cap
- 68M
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- Not available
- Beta
- 0.62
About
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MNOV discussion.
5 years, 4 months ago
MediciNova, Inc is currently in a long term downtrend where the price is trading 24.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
MediciNova, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 50.5% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 17.8% to $-2M since the same quarter in the previous year.
Based on the above factors, MediciNova, Inc gets an overall score of 2/5.